585 related articles for article (PubMed ID: 32707672)
1. Therapeutic Strategies for Overcoming Immunotherapy Resistance Mediated by Immunosuppressive Factors of the Glioblastoma Microenvironment.
Miyazaki T; Ishikawa E; Sugii N; Matsuda M
Cancers (Basel); 2020 Jul; 12(7):. PubMed ID: 32707672
[TBL] [Abstract][Full Text] [Related]
2. Understanding the immunosuppressive microenvironment of glioma: mechanistic insights and clinical perspectives.
Lin H; Liu C; Hu A; Zhang D; Yang H; Mao Y
J Hematol Oncol; 2024 May; 17(1):31. PubMed ID: 38720342
[TBL] [Abstract][Full Text] [Related]
3. Dissecting the immunosuppressive tumor microenvironments in Glioblastoma-on-a-Chip for optimized PD-1 immunotherapy.
Cui X; Ma C; Vasudevaraja V; Serrano J; Tong J; Peng Y; Delorenzo M; Shen G; Frenster J; Morales RT; Qian W; Tsirigos A; Chi AS; Jain R; Kurz SC; Sulman EP; Placantonakis DG; Snuderl M; Chen W
Elife; 2020 Sep; 9():. PubMed ID: 32909947
[TBL] [Abstract][Full Text] [Related]
4. Combination immunotherapy strategies for glioblastoma.
Chan HY; Choi J; Jackson C; Lim M
J Neurooncol; 2021 Feb; 151(3):375-391. PubMed ID: 33611705
[TBL] [Abstract][Full Text] [Related]
5. Role of myeloid cells in the immunosuppressive microenvironment in gliomas.
Locarno CV; Simonelli M; Carenza C; Capucetti A; Stanzani E; Lorenzi E; Persico P; Della Bella S; Passoni L; Mavilio D; Bonecchi R; Locati M; Savino B
Immunobiology; 2020 Jan; 225(1):151853. PubMed ID: 31703822
[TBL] [Abstract][Full Text] [Related]
6. Infiltration of CD163-positive macrophages in glioma tissues after treatment with anti-PD-L1 antibody and role of PI3Kγ inhibitor as a combination therapy with anti-PD-L1 antibody in in vivo model using temozolomide-resistant murine glioma-initiating cells.
Miyazaki T; Ishikawa E; Matsuda M; Sugii N; Kohzuki H; Akutsu H; Sakamoto N; Takano S; Matsumura A
Brain Tumor Pathol; 2020 Apr; 37(2):41-49. PubMed ID: 31980975
[TBL] [Abstract][Full Text] [Related]
7. Immunogenomic analysis reveals LGALS1 contributes to the immune heterogeneity and immunosuppression in glioma.
Chen Q; Han B; Meng X; Duan C; Yang C; Wu Z; Magafurov D; Zhao S; Safin S; Jiang C; Cai J
Int J Cancer; 2019 Jul; 145(2):517-530. PubMed ID: 30613962
[TBL] [Abstract][Full Text] [Related]
8. Targeting FGL2 in glioma immunosuppression and malignant progression.
Ma X; Zhu H; Cheng L; Chen X; Shu K; Zhang S
Front Oncol; 2022; 12():1004700. PubMed ID: 36313679
[TBL] [Abstract][Full Text] [Related]
9. Immunosuppression in Glioblastoma: Current Understanding and Therapeutic Implications.
Himes BT; Geiger PA; Ayasoufi K; Bhargav AG; Brown DA; Parney IF
Front Oncol; 2021; 11():770561. PubMed ID: 34778089
[TBL] [Abstract][Full Text] [Related]
10. Immunotherapy: a promising approach for glioma treatment.
Yasinjan F; Xing Y; Geng H; Guo R; Yang L; Liu Z; Wang H
Front Immunol; 2023; 14():1255611. PubMed ID: 37744349
[TBL] [Abstract][Full Text] [Related]
11. The immune cell landscape of glioblastoma patients highlights a myeloid-enriched and immune suppressed microenvironment compared to metastatic brain tumors.
Musca B; Russo MG; Tushe A; Magri S; Battaggia G; Pinton L; Bonaudo C; Della Puppa A; Mandruzzato S
Front Immunol; 2023; 14():1236824. PubMed ID: 37936683
[TBL] [Abstract][Full Text] [Related]
12. The CNS and the Brain Tumor Microenvironment: Implications for Glioblastoma Immunotherapy.
Desland FA; Hormigo A
Int J Mol Sci; 2020 Oct; 21(19):. PubMed ID: 33027976
[TBL] [Abstract][Full Text] [Related]
13. The role of extracellular vesicles and PD-L1 in glioblastoma-mediated immunosuppressive monocyte induction.
Himes BT; Peterson TE; de Mooij T; Garcia LMC; Jung MY; Uhm S; Yan D; Tyson J; Jin-Lee HJ; Parney D; Abukhadra Y; Gustafson MP; Dietz AB; Johnson AJ; Dong H; Maus RL; Markovic S; Lucien F; Parney IF
Neuro Oncol; 2020 Jul; 22(7):967-978. PubMed ID: 32080744
[TBL] [Abstract][Full Text] [Related]
14. Advances in Nanotechnology-Based Immunotherapy for Glioblastoma.
Tang L; Zhang M; Liu C
Front Immunol; 2022; 13():882257. PubMed ID: 35651605
[TBL] [Abstract][Full Text] [Related]
15. Immune Checkpoint Inhibitors and Glioblastoma: A Review on Current State and Future Directions.
Ser MH; Webb MJ; Sener U; Campian JL
J Immunother Precis Oncol; 2024 May; 7(2):97-110. PubMed ID: 38721406
[TBL] [Abstract][Full Text] [Related]
16. Immunosuppressive Myeloid Cells' Blockade in the Glioma Microenvironment Enhances the Efficacy of Immune-Stimulatory Gene Therapy.
Kamran N; Kadiyala P; Saxena M; Candolfi M; Li Y; Moreno-Ayala MA; Raja N; Shah D; Lowenstein PR; Castro MG
Mol Ther; 2017 Jan; 25(1):232-248. PubMed ID: 28129117
[TBL] [Abstract][Full Text] [Related]
17. The immunosuppressive microenvironment and immunotherapy in human glioblastoma.
Zhang X; Zhao L; Zhang H; Zhang Y; Ju H; Wang X; Ren H; Zhu X; Dong Y
Front Immunol; 2022; 13():1003651. PubMed ID: 36466873
[TBL] [Abstract][Full Text] [Related]
18. Overcoming the immune suppressive nature of glioblastoma by leveraging the surgical intervention - current status and future perspectives.
Duerinck J; Tuyaerts S; Movahedi K; Neyns B
Front Immunol; 2023; 14():1183641. PubMed ID: 37275902
[TBL] [Abstract][Full Text] [Related]
19. The Current Landscape of Immune Checkpoint Blockade in Glioblastoma.
Akintola OO; Reardon DA
Neurosurg Clin N Am; 2021 Apr; 32(2):235-248. PubMed ID: 33781505
[TBL] [Abstract][Full Text] [Related]
20. T lymphocyte-targeted immune checkpoint modulation in glioma.
Kelly WJ; Giles AJ; Gilbert M
J Immunother Cancer; 2020 Feb; 8(1):. PubMed ID: 32051289
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
